Sex: U
Vaccine: FLUX
Symptoms: Influenza
Clinical narrative: Initial unsolicited report received from a literature on 07-Dec-2015. Abstract: BACKGROUND: The moderate level of protection conferred by influenza vaccines is well-known, but the vaccine's ability to attenuate symptom severity among vaccinated individuals (i.e., vaccine failures) has not been established. METHODS: We enrolled otherwise healthy adults who presented with influenza-like illness (ILI) at five hospitals between 2009 and 2014. Influenza was diagnosed and subtyped by PCR. Individual and composite severity scores were compared between those who had vs. had not received the seasonal influenza vaccine greater than 14 days prior to enrollment. RESULTS: A total of 155 cases of influenza (A/H1N1, n equal to 69; A/H3N2, n equal to 66; A/untyped, n equal to 3; B, n equal to 17) were identified, of whom 111 (72 percent; A/H1N1, n equal to 44; A/H3N2, n equal to 52; A/untyped, n equal to 3; B, n equal to 12) had been vaccinated. Women were significantly less likely to be vaccinated than men (49 percent vs. 89 percent; less than 01). In multivariate analysis, vaccinated individuals were significantly less likely to report a fever greater than 101 Degrees Fahrenheit (OR 0.24; 95 percent CI [0.10, 0.62]) and more likely to report myalgias (OR 3.31; 95 percent CI [1.22, 8.97]) than vaccinated individuals. Among patients with A/H3N2 infection, upper respiratory and total symptom severity scores were significantly lower for vaccinated patients during the first 2 days of illness, and differences in total symptom severity persisted over 7 days (p less than 0.05 for all comparisons). Differences across additional symptom categories (lower respiratory and systemic) were also observed throughout 7 days of illness in bivariate analyses. Difference in symptom severity were not observed between vaccinated and unvaccinated participants with A/H1N1 infection. CONCLUSIONS: Among patients with A/H3N2 infection, receipt of seasonal influenza vaccine was associated with reduced symptom severity. Patient-centered discussion about the benefits of influenza vaccination should be expanded to include the possibility that the vaccine could attenuate symptoms. The aforementioned information retrieved from full text article. This case involves a 59 patients who were vaccinated with a dose of influenza vaccine (Manufacturer: unknown, batch number, route and site of administration were not reported) on an unspecified date. Medical history and concomitant medications were not reported. On an unspecified dates, after vaccination patients experienced influenza. It was reported that total symptom severity scores were significantly lower for vaccinated patients during the first 2 days of illness, and differences in total symptom severity persisted over 7 days  (p less than 0.05 for all comparisons). Differences across additional symptom categories (lower respiratory and systemic) were also observed throughout 7 days of illness in bivariate analyses. Lab tests were not reported. Patients were prescribed with Antiviral medications. Outcome of the event was not reported. Upon internal review, case was considered as serious due to important medical event: influenza. List of documents held by sender: none.